[go: up one dir, main page]

GB0100110D0 - Modulation of calcium channel activity - Google Patents

Modulation of calcium channel activity

Info

Publication number
GB0100110D0
GB0100110D0 GBGB0100110.6A GB0100110A GB0100110D0 GB 0100110 D0 GB0100110 D0 GB 0100110D0 GB 0100110 A GB0100110 A GB 0100110A GB 0100110 D0 GB0100110 D0 GB 0100110D0
Authority
GB
United Kingdom
Prior art keywords
modulation
calcium channel
channel activity
activity
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0100110.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Priority to GBGB0100110.6A priority Critical patent/GB0100110D0/en
Publication of GB0100110D0 publication Critical patent/GB0100110D0/en
Priority to PCT/GB2002/000013 priority patent/WO2002059155A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0100110.6A 2001-01-04 2001-01-04 Modulation of calcium channel activity Ceased GB0100110D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0100110.6A GB0100110D0 (en) 2001-01-04 2001-01-04 Modulation of calcium channel activity
PCT/GB2002/000013 WO2002059155A2 (en) 2001-01-04 2002-01-03 Modulation of calcium channel activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0100110.6A GB0100110D0 (en) 2001-01-04 2001-01-04 Modulation of calcium channel activity

Publications (1)

Publication Number Publication Date
GB0100110D0 true GB0100110D0 (en) 2001-02-14

Family

ID=9906193

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0100110.6A Ceased GB0100110D0 (en) 2001-01-04 2001-01-04 Modulation of calcium channel activity

Country Status (2)

Country Link
GB (1) GB0100110D0 (en)
WO (1) WO2002059155A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141588B2 (en) 2002-02-25 2006-11-28 Pfizer, Inc. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
AR038536A1 (en) 2002-02-25 2005-01-19 Upjohn Co N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7304050B2 (en) 2003-09-16 2007-12-04 Pfizer Inc. Antibacterial agents
BRPI0519807A2 (en) 2005-01-12 2009-03-17 Sanofi Aventis use of a trpc channel to treat cardiovascular disease
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JO3598B1 (en) * 2006-10-10 2020-07-05 Infinity Discovery Inc Boronic acids and esters as inhibitors of fatty acid amide hydrolase
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
JP5637982B2 (en) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド Inhibitors of fatty acid amide hydrolase
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
CN102834401B (en) 2010-02-03 2016-08-24 无限药品股份有限公司 Inhibitors of fatty acid amide hydrolase
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.

Also Published As

Publication number Publication date
WO2002059155A2 (en) 2002-08-01
WO2002059155A3 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
GB2383706B (en) Modulation control
GB0100110D0 (en) Modulation of calcium channel activity
AU2002366103A8 (en) Modulators of rho c activity
AU2002364125A8 (en) Antisense modulation of mdm2 expression
GB0122914D0 (en) Modulation of stat activity
ZA200206318B (en) Modulation of bone formation.
AU2002366788A8 (en) Antisense modulation of ship-1 expression
GB0126781D0 (en) Modulation
GB0124321D0 (en) Modulation determination
IL156804A0 (en) Modulation of gsk-3beta activity and its different uses
AU2002357102A8 (en) Antisense modulation of cd36l1 expression
AU2003257966A8 (en) Antisense modulation of lar expression
IL162747A0 (en) Modulation of heat-shock-protein-based immunotherapies
AU2003297897A8 (en) Modulation of stat 6 expression
AU2002360405A8 (en) Modulators of rho c activity
EP1453470A4 (en) Modulators of rho c activity
AU2003295790A8 (en) Modulation of iap-like expression
AU2003299204A8 (en) Focal calcium channel modulation
AU2002217314A1 (en) Modulation of calcium channel activity
AU2002359428A8 (en) Modulators of rho c activity
AU2002357101A8 (en) Antisense modulation of cd81 expression
AU2003271988A8 (en) Modulation of tgfbeta-like signalling pathways
AU2003243589A8 (en) Antisense modulation of smrt expression
IL158413A0 (en) Treatment of adhd
GB0026727D0 (en) Modulation of PDEII activity

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)